Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.98 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | HTT | P42858 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.98 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12119008 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL472771 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL27097764 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL17033118 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL145857 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL472589 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL16081270 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL472588 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| N6-Cyclopentyladenosine SCHEMBL18908968 | 0.99 | ADORA3 (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| N6-Cyclopentyladenosine SCHEMBL120481 | 0.99 | ADORA3 (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911408-B2 | Synergistic formulations of adenosine receptor modulating agents and anticholinergics | UNIVERSITY OF ALASKA FAIRBANKS (US) | 2024-02-27 | — | — | US | claimed |
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| CN-117338801-A | Application of N6-substituted adenosine derivative or N6-substituted purine derivative in preparation of medicine for relieving peri-operative neuroinflammation | 河北医科大学 | 2024-01-05 | — | — | CN | claimed |
| CN-114376962-A | Drug-loaded nanofiber for acupuncture point thread embedding material and preparation method and application thereof | 上海市第四人民医院 | 2022-04-22 | — | — | CN | claimed |
| WO-2021003393-A1 | METHOD, COMPOSITION, AND APPARATUS FOR TREATING HEADACHE | Equinox Ophthalmic, Inc. (US) | 2021-01-07 | — | — | WO | claimed |
| CN-111789950-A | Method and pharmaceutical composition for regulating fear memory consolidation | 浙江大学 | 2020-10-20 | — | — | CN | claimed |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | UNIV ROCHESTER (US) | 2020-09-03 | — | — | US | claimed |
| US-20190125779-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-05-02 | — | — | US | claimed |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | claimed |
| WO-2017137528-A1 | ADENOSINE A1 RECEPTOR AGONIST FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2017-08-17 | — | — | WO | claimed |
| WO-2009071094-A2 | COMBINATION TREATMENT OF ISCHEMIC EFFECTS | NEUROKEY A/S (DK) | 2009-06-11 | — | — | WO | claimed |
| WO-2009071096-A2 | COMBINATION OF MEDICAL AND PHYSICAL COOLING TREATMENT OF ISCHEMIC EFFECTS | NEUROKEY A/S (DK) | 2009-06-11 | — | — | WO | claimed |
| WO-2009018275-A1 | ADENOSINE AND ITS MIMETICS, MODULATORS, TRANSPORT INHIBITORS, AND RECEPTOR AGONISTS AS A THERAPEUTIC TOOL TO REPLACE OR IMPROVE THE EFFICACY OF DEEP BRAIN STIMULATION | UNIVERSITY OF ROCHESTER (US) | 2009-02-05 | — | — | WO | claimed |
| US-20070232560-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2007-10-04 | — | — | US | claimed |
| US-20060240056-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2006-10-26 | — | — | US | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| EP-0996453-B1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 2004-04-28 | — | — | EP | claimed |
| CN-1466591-A | Nucleoside derivatives | - | 2004-01-07 | — | — | CN | claimed |
| US-6638914-B1 | Use in inducing proliferation of the hematopoietic system, in particular, of bone marrow cells, comprising a pharmaceutically acceptable carrier, excipient or diluent and, as an active ingredient, an effective amount of an | CAN-FITE BIOPHARMA LTD. (IL) | 2003-10-28 | — | — | US | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | TSHR 4452/4885ADORA2A 70/4885PMP22 4754/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | TSHR 4452/4885ADORA2A 70/4885PMP22 4754/4885 |
| US-11911408-B2 | Synergistic formulations of adenosine receptor modulating agents and anticholinergics | ADORA1, ADORA3, ADORA2A | TSHR 235/4885ADORA2A 3/4885PMP22 4619/4885 |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | TSHR 3522/4885ADORA2A 10/4885PMP22 2993/4885 |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | P2RX3, P2RX1, P2RX2 | TSHR 2680/4885ADORA2A 8/4885PMP22 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.